<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127125</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20130458H</org_study_id>
    <nct_id>NCT02127125</nct_id>
  </id_info>
  <brief_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)</brief_title>
  <acronym>MicroB2</acronym>
  <official_title>Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether microbiome modulation and an experimental&#xD;
      reduction in plasma LPS concentration improve inflammation and insulin action in insulin&#xD;
      resistant (obese and T2DM) subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this Aim we will test the hypothesis that lowering lipopolysaccharide (LPS) concentration&#xD;
      in the circulation will improve systemic (muscle) inflammation and glucose metabolism in&#xD;
      insulin resistant (obese and T2DM) subjects by protecting the intestinal barrier with a&#xD;
      synbiotic (Bifidobacterium longum R0175 and oligofructose) or by sequestering LPS in the&#xD;
      gastrointestinal lumen with sevelamer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2014</start_date>
  <completion_date type="Actual">September 10, 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Change from baseline insulin sensitivity at 28 days of the intervention.</time_frame>
    <description>Insulin sensitivity in skeletal muscle (M value) as measured by hyperinsulinemic euglycemic clamp study. The clamp study tests the ability of peripheral tissues such as skeletal muscle to uptake glucose in response to a constant insulin stimulus, which give a measure of sensitivity to insulin action. 60 mU/m2*min insulin was infused into subjects for 180 minutes with concomitant adjustment of glucose infusion rate using D20 glucose to maintain a clamped plasma glucose concentration of 100 mg/dL. When the glucose infusion rate equals the rate of glucose uptake and the targeted glucose concentration is achieved, the clamp is at steady-state equilibrium. Steady-state glucose infusion rate at 150min-180mins was used as the measure to calculate the M value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Endotoxin Level and Its Panel.</measure>
    <time_frame>Change from baseline plasma endotoxin level and its panel during 28 days.</time_frame>
    <description>Plasma Lipopolysaccharide (LPS) after intervention period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut Permeability</measure>
    <time_frame>Change from baseline gut permeability at 24 days of the intervention.</time_frame>
    <description>urine lactulose: mannitol ratio.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>Type2 Diabetes Mellitus - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Type 2 Diabetes Mellitus subjects will receive maltodextrin (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with NGT - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) subjects will receive maltodextrin (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean with NGT -Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant (NGT) will receive maltodextrin (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type2 Diabetes Mellitus - Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 Diabetic subjects will receive synbiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Type2 Diabetes Mellitus - Sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 Diabetic subjects will receive sevelamer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with NGT - Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant subjects (NGT) will receive Synbiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Obese with NGT - Sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obese subjects (BMI = 30-37 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean with NGT - Synbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant (NGT) will receive Synbiotic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean with NGT - Sevelamer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant (NGT) will receive Sevelamer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maltodextrin</intervention_name>
    <description>Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
    <arm_group_label>Lean with NGT -Placebo</arm_group_label>
    <arm_group_label>Obese with NGT - Placebo</arm_group_label>
    <arm_group_label>Type2 Diabetes Mellitus - Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <description>Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
    <arm_group_label>Lean with NGT - Synbiotic</arm_group_label>
    <arm_group_label>Obese with NGT - Synbiotic</arm_group_label>
    <arm_group_label>Type2 Diabetes Mellitus - Synbiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <description>Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
    <arm_group_label>Lean with NGT - Sevelamer</arm_group_label>
    <arm_group_label>Obese with NGT - Sevelamer</arm_group_label>
    <arm_group_label>Type2 Diabetes Mellitus - Sevelamer</arm_group_label>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both genders (50%, male). All races and ethnic groups.&#xD;
&#xD;
          -  Premenopausal women in the follicular phase, non-lactating, and with a negative&#xD;
             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone&#xD;
             replacement for ≥6 months.&#xD;
&#xD;
          -  Hematocrit (HCT)≥ 34%, serum creatinine ≤ 1.4 mg/dl, and normal results of serum&#xD;
             electrolytes, urinalysis, and coagulation tests. Liver function tests (LFTs) up to 2&#xD;
             times normal&#xD;
&#xD;
          -  Stable body weight (±2%) for ≥ 3 months.&#xD;
&#xD;
          -  Two or less sessions of strenuous exercise/wk for last 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current treatment with drugs known to affect glucose and lipid homeostasis. If the&#xD;
             subject has been on a stable dose for the past 3 months, the following agents will be&#xD;
             permitted: calcium channel blockers, β-blockers, ACE inhibitors, angiotensin receptor&#xD;
             blockers, and statins&#xD;
&#xD;
          -  History of allergy to sevelamer.&#xD;
&#xD;
          -  Non-steroidal anti-inflammatory drugs or systemic steroid use for more than a week&#xD;
             within 3 months.&#xD;
&#xD;
          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and&#xD;
             clopidogrel will be permitted if these can be held for seven days prior to the biopsy&#xD;
             in accordance with the primary physician.&#xD;
&#xD;
          -  Use of agents that affect gut flora (e.g. antibiotics, colestyramine, lactulose, PEG)&#xD;
             within 3 months.&#xD;
&#xD;
          -  History of heart disease (New York Heart Classification greater than grade II; more&#xD;
             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,&#xD;
             pulmonary disease, smokers.&#xD;
&#xD;
          -  Poorly controlled blood pressure (systolic BP&gt;170, diastolic BP&gt;95 mmHg).&#xD;
&#xD;
          -  Active inflammatory, autoimmune, hepatic, gastrointestinal, malignant, and psychiatric&#xD;
             disease.&#xD;
&#xD;
          -  History of gastrointestinal surgery or gastrointestinal obstruction within two years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital, STVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>April 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2014</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 11, 2020</results_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02127125/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>69 participants were screened, 8 were screen failures, so not randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lean With NGT-Placebo</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Lean With NGT-Sevelamer</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Lean With NGT-Synbiotic</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Obese With NGT-Placebo</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks</description>
        </group>
        <group group_id="P5">
          <title>Obese With NGT-Sevelamer</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="P6">
          <title>Obese With NGT-Synbiotic</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Type 2 Diabetes -Placebo</title>
          <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="P8">
          <title>Type 2 Diabetes-Sevelamer</title>
          <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="P9">
          <title>Type 2 Diabetes-Synbiotic</title>
          <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Low enrollment of Type 2 Diabetics in this study due to exclusionary medication criteria including many common diabetes medications such as metformin which interfere with microbiome content. Subjects were randomized to treatment and no diabetic subjects ended up in the sevelamer treatment group.</population>
      <group_list>
        <group group_id="B1">
          <title>Lean With NGT-Placebo</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Lean With NGT-Sevelamer</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Lean With NGT-Synbiotic</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Obese With NGT-Placebo</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Obese With NGT-Sevelamer</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="B6">
          <title>Obese With NGT-Synbiotic</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Type 2 Diabetes-Placebo</title>
          <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Type 2 Diabetes-Sevelamer</title>
          <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="B9">
          <title>Type 2 Diabetes-Synbiotic</title>
          <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="9"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="0"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="14.3"/>
                    <measurement group_id="B2" value="46.9" spread="15.7"/>
                    <measurement group_id="B3" value="48.8" spread="12.7"/>
                    <measurement group_id="B4" value="51.6" spread="9.5"/>
                    <measurement group_id="B5" value="51.7" spread="12.4"/>
                    <measurement group_id="B6" value="50.3" spread="8.4"/>
                    <measurement group_id="B7" value="61.0" spread="1.4"/>
                    <measurement group_id="B9" value="52.0" spread="0.0"/>
                    <measurement group_id="B10" value="49.2" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity</title>
        <description>Insulin sensitivity in skeletal muscle (M value) as measured by hyperinsulinemic euglycemic clamp study. The clamp study tests the ability of peripheral tissues such as skeletal muscle to uptake glucose in response to a constant insulin stimulus, which give a measure of sensitivity to insulin action. 60 mU/m2*min insulin was infused into subjects for 180 minutes with concomitant adjustment of glucose infusion rate using D20 glucose to maintain a clamped plasma glucose concentration of 100 mg/dL. When the glucose infusion rate equals the rate of glucose uptake and the targeted glucose concentration is achieved, the clamp is at steady-state equilibrium. Steady-state glucose infusion rate at 150min-180mins was used as the measure to calculate the M value.</description>
        <time_frame>Change from baseline insulin sensitivity at 28 days of the intervention.</time_frame>
        <population>Enrollment and completion for Type 2 diabetes mellitus group was low due to exclusionary criteria that prevented most diabetes medications from being used while in the study. Lean with NGT and Obese with NGT groups completed 6 control, 8 sevelamer, 8 synbiotic subjects for Lean group and 10 control, 9 sevelamer and 9 synbiotic for Obese group.</population>
        <group_list>
          <group group_id="O1">
            <title>Lean With NGT-Placebo</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lean With NGT-Sevelamer</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Lean With NGT-Synbiotic</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Obese With NGT-Placebo</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Obese With NGT-Sevelamer</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Obese With NGT-Synbiotic</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Type 2 Diabetes-Placebo</title>
            <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Type 2 Diabetes-Sevelamer</title>
            <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O9">
            <title>Type 2 Diabetes-Synbiotic</title>
            <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Insulin sensitivity in skeletal muscle (M value) as measured by hyperinsulinemic euglycemic clamp study. The clamp study tests the ability of peripheral tissues such as skeletal muscle to uptake glucose in response to a constant insulin stimulus, which give a measure of sensitivity to insulin action. 60 mU/m2*min insulin was infused into subjects for 180 minutes with concomitant adjustment of glucose infusion rate using D20 glucose to maintain a clamped plasma glucose concentration of 100 mg/dL. When the glucose infusion rate equals the rate of glucose uptake and the targeted glucose concentration is achieved, the clamp is at steady-state equilibrium. Steady-state glucose infusion rate at 150min-180mins was used as the measure to calculate the M value.</description>
          <population>Enrollment and completion for Type 2 diabetes mellitus group was low due to exclusionary criteria that prevented most diabetes medications from being used while in the study. Lean with NGT and Obese with NGT groups completed 6 control, 8 sevelamer, 8 synbiotic subjects for Lean group and 10 control, 9 sevelamer and 9 synbiotic for Obese group.</population>
          <units>M Value (mg/kg/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="3.78"/>
                    <measurement group_id="O2" value="8.45" spread="2.25"/>
                    <measurement group_id="O3" value="9.47" spread="2.59"/>
                    <measurement group_id="O4" value="5.96" spread="2.24"/>
                    <measurement group_id="O5" value="8.14" spread="2.138"/>
                    <measurement group_id="O6" value="5.45" spread="1.88"/>
                    <measurement group_id="O7" value="3.81" spread=".386"/>
                    <measurement group_id="O9" value="1.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Sevelamer treated Obese subjects with normal glucose tolerance will show no post-treatment change in insulin sensitivity compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.025</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Synbiotic treated Obese subjects with normal glucose tolerance will show no post-treatment change in insulin sensitivity compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Endotoxin Level and Its Panel.</title>
        <description>Plasma Lipopolysaccharide (LPS) after intervention period</description>
        <time_frame>Change from baseline plasma endotoxin level and its panel during 28 days.</time_frame>
        <population>Poor recruitment for type 2 diabetic group means few subjects analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Lean With NGT-Placebo</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lean With NGT-Sevelamer</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Lean With NGT-Synbiotic</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Obese With NGT-Placebo</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Obese With NGT-Sevelamer</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Obese With NGT-Synbiotic</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Type 2 Diabetes-Placebo</title>
            <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Type 2 Diabetes-Sevelamer</title>
            <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O9">
            <title>Type 2 Diabetes-Synbiotic</title>
            <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Endotoxin Level and Its Panel.</title>
          <description>Plasma Lipopolysaccharide (LPS) after intervention period</description>
          <population>Poor recruitment for type 2 diabetic group means few subjects analyzed.</population>
          <units>Endotoxin units/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4452" spread="0.1987"/>
                    <measurement group_id="O2" value="0.5634" spread="0.1713"/>
                    <measurement group_id="O3" value="0.6925" spread="0.5907"/>
                    <measurement group_id="O4" value="0.6230" spread="0.1976"/>
                    <measurement group_id="O5" value="0.8012" spread="0.4187"/>
                    <measurement group_id="O6" value="0.7195" spread="0.2905"/>
                    <measurement group_id="O7" value="0.2961"/>
                    <measurement group_id="O9" value="0.4062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Sevelamer treated Obese subjects with normal glucose tolerance will show no post-treatment change in insulin sensitivity compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Synbiotic treated Obese subjects with normal glucose tolerance will show no post-treatment change in insulin sensitivity compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gut Permeability</title>
        <description>urine lactulose: mannitol ratio.</description>
        <time_frame>Change from baseline gut permeability at 24 days of the intervention.</time_frame>
        <population>One obese sevelamer subject was not able to complete their baseline Lactulose: Mannitol ratio assay, thus cannot evaluate pre-post effect from their study.</population>
        <group_list>
          <group group_id="O1">
            <title>Lean With NGT-Placebo</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Lean With NGT-Sevelamer</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Lean With NGT-Synbiotic</title>
            <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Obese With NGT-Placebo</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Obese With NGT-Sevelamer</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O6">
            <title>Obese With NGT-Synbiotic</title>
            <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
          <group group_id="O7">
            <title>Type 2 Diabetes-Placebo</title>
            <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
          </group>
          <group group_id="O8">
            <title>Type 2 Diabetes-Sevelamer</title>
            <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
          </group>
          <group group_id="O9">
            <title>Type 2 Diabetes-Synbiotic</title>
            <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Gut Permeability</title>
          <description>urine lactulose: mannitol ratio.</description>
          <population>One obese sevelamer subject was not able to complete their baseline Lactulose: Mannitol ratio assay, thus cannot evaluate pre-post effect from their study.</population>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02262" spread="0.006856"/>
                    <measurement group_id="O2" value="0.02164" spread="0.008943"/>
                    <measurement group_id="O3" value="0.02349" spread="0.008680"/>
                    <measurement group_id="O4" value="0.02055" spread="0.01018"/>
                    <measurement group_id="O5" value="0.01635" spread="0.006882"/>
                    <measurement group_id="O6" value="0.01952" spread="0.004869"/>
                    <measurement group_id="O7" value="0.02662" spread="0.004186"/>
                    <measurement group_id="O9" value="0.01979"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Sevelamer treated Obese subjects with normal glucose tolerance will show no post-treatment change in Lactulose:Mannitol ratio compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that Synbiotic treated Obese subjects with normal glucose tolerance will show no post-treatment change in Lactulose:Mannitol ratio compared to placebo treated subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>p-value not adjusted for multiple comparison, a priori threshold for significance set at p&lt;0.025 for multiple comparisons.</p_value_desc>
            <method>Generalized Estimating Equation</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Study participants were enrolled in the study for approximately 2-3 months.</time_frame>
      <desc>Adverse Event data was collected over the course of the subject's participation in the study, often at followup visits as part of biopsy site checks.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lean With NGT-Placebo</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Lean With NGT-Sevelamer</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Lean With NGT-Synbiotic</title>
          <description>Lean (BMI&lt; 26 kg/m2) normal glucose tolerant Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Obese With NGT-Placebo</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Obese With NGT-Sevelamer</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="E6">
          <title>Obese With NGT-Synbiotic</title>
          <description>Obese (BMI = 30-37 kg/m2) normal glucose tolerant. Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Type 2 Diabetes-Placebo</title>
          <description>Type 2 Diabetics Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Type 2 Diabetes-Sevelamer</title>
          <description>Type 2 Diabetics Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks</description>
        </group>
        <group group_id="E9">
          <title>Type 2 Diabetes-Synbiotic</title>
          <description>Type 2 Diabetics Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal Bloating/Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia Exacerbation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache/Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Biopsy Site Pain/soreness</sub_title>
                <description>Biopsies of the vastus lateralis are obtained under local anesthesia at visit 4 and 6, before and after insulin clamp. All events expected given procedure protocol.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nicolas Musi</name_or_title>
      <organization>San Antonio Geriatric Research, Education, and Clinical Center</organization>
      <phone>(210) 562-6140</phone>
      <email>musi@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

